Stablix is pioneering an entirely new field of targeted deubiquitination therapeutics (TDT) to bring transformative medicines to patients with unmet medical need. Co-located in New York City and Boston, we are a creative and multidisciplinary team of scientists, innovators and leaders dedicated to changing the way we approach drug development by establishing a powerful small-molecule modality for a wide variety of devastating diseases.